Effect of Evolocumab on Coronary Plaque Composition

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Coronary atherosclerosis is a significant health concern.
• Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors like evolocumab offer a novel approach to lowering low-density lipoprotein (LDL) cholesterol.
• Understanding the impact of PCSK9 inhibition on plaque composition is crucial for cardiovascular risk management.

Purpose of the Study:

• To investigate the effect of adding evolocumab to statin therapy on the composition of coronary atherosclerotic plaque.
• To determine if evolocumab induces changes in plaque morphology beyond LDL cholesterol reduction.

Main Methods:

• A randomized controlled trial involving 968 statin-treated patients with coronary artery disease.
• Serial coronary intravascular ultrasound imaging was performed at baseline and after 76 weeks of treatment with either placebo or evolocumab (420 mg monthly).
• Plaque composition analysis using radiofrequency analysis of ultrasound backscatter was conducted in a subset of 331 patients.

Main Results:

• Evolocumab significantly reduced LDL cholesterol by an additional 33.5 mg/dl compared to statin monotherapy (p < 0.0001).
• Treatment with evolocumab resulted in a significant regression of percent atheroma volume (-1.2% vs. +0.17%; p < 0.0001) and total atheroma volume (-3.6 mm³ vs. -0.8 mm³; p = 0.04).
• No significant differences were observed in the changes of specific plaque components (calcium, fibrous, fibrofatty, necrotic volumes) between the evolocumab and placebo groups.

Conclusions:

• Adding evolocumab to statin therapy effectively reduces LDL cholesterol and coronary plaque burden.
• Evolocumab does not induce differential changes in plaque composition compared to statin monotherapy.
• Virtual histology imaging may not provide additional information on evolocumab's plaque effects beyond plaque burden measurements.